当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

抽象的な

Need for Artificial Intelligence in Pharmaceutical Industry and its Limitations

Varun Pareek, Lokendra Sharma, Sushil Kumar

AI is often being touted as the means to bring about the fourth Industrial Revolution and its role in almost all sectors of our society is almost certain. This brings about an urgent need for evaluating benefits and limitations of AI and machine learning across various sectors. Pharmaceutical industry has pioneered in embracing the use of AI in all of its core areas but the success as of yet seems very limited. The major advantage of AI is that it reduces the time that is needed for drug development and, in turn, it reduces the costs that are associated with drug development, enhances the returns on investment and may even cause a decrease in cost for the end user along with improved drug safety. So in this article we will review the scope and limitations of AI in the pharmaceutical industry.